| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 01.03. | ANAGENICS LIMITED: Appendix 3X MR JOSHUA GORDON | - | ASX | ||
| 01.03. | ANAGENICS LIMITED: AN1 - Director Appointment | - | ASX | ||
| 27.02. | ANAGENICS LIMITED: Change of Director's Interest Notice | 1 | ASX | ||
| 25.02. | ANAGENICS LIMITED: AN1 - 1H FY26 Presentation | 1 | ASX | ||
| 24.02. | ANAGENICS LIMITED: Anagenics - 1H FY26 Result Highlights | - | ASX | ||
| ANAGENICS Aktie jetzt für 0€ handeln | |||||
| 24.02. | ANAGENICS LIMITED: Anagenics - 1H26 HY Report DEC 2025 | - | ASX | ||
| 24.02. | ANAGENICS LIMITED: Appendix 4D 1H FY26 DEC 2025 | - | ASX | ||
| 12.02. | ANAGENICS LIMITED: Becoming a substantial holder | - | ASX | ||
| 12.02. | ANAGENICS LIMITED: Becoming a substantial holder | - | ASX | ||
| 12.02. | ANAGENICS LIMITED: Notification regarding unquoted securities - AN1 | 1 | ASX | ||
| 09.02. | ANAGENICS LIMITED: Ceasing to be a substantial holder from FOS | 1 | ASX | ||
| 09.02. | ANAGENICS LIMITED: Change in substantial holding from HNG | 1 | ASX | ||
| 08.02. | ANAGENICS LIMITED: Application for quotation of securities - AN1 | - | ASX | ||
| 29.01. | ANAGENICS LIMITED: Notification of cessation of securities - AN1 | 1 | ASX | ||
| 29.01. | ANAGENICS LIMITED: Notification of cessation of securities - AN1 | 1 | ASX | ||
| 29.01. | ANAGENICS LIMITED: Appendix 4C & Activity Report for Q2 FY2026 | 5 | ASX | ||
| 29.01. | ANAGENICS LIMITED: Results of Meeting | - | ASX | ||
| 29.01. | ANAGENICS LIMITED: Change of Address | - | ASX | ||
| 05.01. | ANAGENICS LIMITED: Change in substantial holding from FOS | - | ASX | ||
| 05.01. | ANAGENICS LIMITED: Change in substantial holding from HNG | 1 | ASX |
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| NOVO NORDISK | 31,920 | +0,76 % | Milliardenmarkt vor Umbruch: Angriff auf Eli Lilly und Novo Nordisk: Roche wittert Milliardenchance | © Foto: Udo Herrmann - picture alliance / CHROMORANGERoche will im boomenden Markt für Abnehm-Medikamente wieder angreifen. Der Konzern setzt auf neue Strategien und Milliarden-Deals im Wettbewerb.Der... ► Artikel lesen | |
| AURORA CANNABIS | 2,885 | -2,86 % | Panik vor Kursbeben: Das Zittern beginnt: Reißen die Tilray-Zahlen Canopy, Aurora & Co in die Tiefe? | © Foto: adobe.stock.comIn Kürze ist es soweit - Tilray wird frische Quartalszahlen vorlegen. Den Tilray-Zahlen kann man dabei durchaus richtungsweisenden Charakter zubilligen. Entsprechend dürften sie... ► Artikel lesen | |
| CANOPY GROWTH | 0,811 | -4,14 % | CANOPY GROWTH CORPORATION - Stabilität vor Bewegung | ||
| TILRAY BRANDS | 5,710 | -4,36 % | Tilray Brands Inc (2): Tilray Brands, Popsicle to launch hard beverages | ||
| VERTEX PHARMACEUTICALS | 394,10 | +0,10 % | Where Will Vertex Pharmaceuticals Be in 1 Year? | ||
| TAAT GLOBAL ALTERNATIVES | 0,136 | -100,00 % | TAAT Global Alternatives Inc (2): TAAT Global CEO Saxon resigns | ||
| CRONOS GROUP | 2,232 | -2,11 % | Cronos Group Inc.: Cronos Group Reports 2025 Fourth Quarter and Full-Year Results | Net revenue in Q4 2025 increased by 47% year-over-year to $44.5 million; Net revenue in FY 2025 increased by 25% year-over-year to $146.6 million Achieved record net revenue in Q4 2025 and FY 2025... ► Artikel lesen | |
| DIGICANN VENTURES | 0,004 | 0,00 % | Digicann Ventures Inc.: Digicann Ventures Announces Agreement to Extend Maturity Date for Convertible Debentures | Vancouver, British Columbia--(Newsfile Corp. - March 12, 2026) - Digicann Ventures Ltd. (CSE: DCNN.X) ("Digicann" or the "Company"), a company focused on opportunities within and outside of the... ► Artikel lesen | |
| ORGANIGRAM GLOBAL | 1,180 | +5,36 % | Organigram Global Inc: Organigram garners ISS support for Sanity transaction | ||
| GREEN THUMB INDUSTRIES | 5,355 | -1,74 % | Green Thumb Industries Reports Fourth Quarter and Full Year 2025 Results | CHICAGO and VANCOUVER, British Columbia, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Green Thumb Industries Inc. ("Green Thumb" or the "Company") (CSE: GTII) (OTCQX: GTBIF), a leading national cannabis consumer... ► Artikel lesen | |
| IONIS PHARMACEUTICALS | 64,40 | +2,45 % | Ionis Pharmaceuticals Repriced Drug Ahead Of Key FDA Decision Signals Push Into Larger Market | ||
| NOVERIS HEALTH SCIENCES | 1,170 | 0,00 % | XFRA 0NF1: AUSSETZUNG/SUSPENSION | DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTILNOVERIS HEALTH SCI.... ► Artikel lesen | |
| WAYLAND GROUP | - | - | EQS-News: Berger Montague (Canada) PC: Ankündigung der Anhörung zur Genehmigung des Vergleichs - Wayland Group Corp., Scott Langille, Gerhard Müller, Paul Pathak, Eric Silver, M. Stein, John Does 1-3, Canaccord Genuity Corp. und RF Securities Clearing LP | EQS-News: Berger Montague (Canada) PC
/ Schlagwort(e): Rechtssache/Sonstiges
ANKÜNDIGUNG DER ANHÖRUNG ZUR GENEHMIGUNG DES VERGLEICHS - KURZFASSUNG - WAYLAND... ► Artikel lesen | |
| SANTHERA PHARMACEUTICALS | 17,160 | +2,26 % | Santhera Pharmaceuticals Holding AG: Full Year 2025 Trading Update | Ad hoc announcement pursuant to Art. 53 LR
AGAMREE continues to build strong commercial momentum, delivering 98% revenue growth
Pratteln, Switzerland, March 12, 2026 - Santhera Pharmaceuticals... ► Artikel lesen | |
| NEKTAR THERAPEUTICS | 62,00 | -0,80 % | Nektar Therapeutics: Data from Phase 2b Studies for Rezpegaldesleukin Accepted for Two Oral Presentations at the 2026 American Academy of Dermatology Annual Meeting | SAN FRANCISCO, March 20, 2026 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) announced today that data from the ongoing Phase 2b studies of rezpegaldesleukin... ► Artikel lesen |